Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 6/20 | 0.63 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.63 |
| ▸ | DNMT3B | Q9UBC3 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | PNP | P00491 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | PIM1 | P11309 | 1/20 | 0.48 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.48 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.48 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.48 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.48 |
| ▸ | TK1 | P04183 | 1/20 | 0.48 |
| ▸ | FPR2 | P25090 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5982343 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| SCHEMBL5982335 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| SCHEMBL12731448 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| SCHEMBL197813 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| Phosphoric Acid SCHEMBL416601 | 0.95 | DNMT1 (0.58) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| SCHEMBL9780830 | 0.91 | DNMT1 (0.52) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| SCHEMBL9780823 | 0.91 | DNMT1 (0.52) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| SCHEMBL5983760 | 0.88 | DNMT1 (0.66) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| SCHEMBL5983766 | 0.88 | DNMT1 (0.66) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| SCHEMBL9856645 | 0.87 | DNMT1 (0.47) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1867 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES, INC. (US) | 2025-08-21 | — | — | US | claimed |
| EP-4271389-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | Rejuvenation Technologies Inc. (US) | 2023-11-08 | — | — | EP | claimed |
| CN-115998630-B | Hair-blacking essence and preparation method thereof | 北京普世安生物科技有限公司 | 2023-06-06 | — | — | CN | claimed |
| CN-115998630-A | Hair-blacking essence and preparation method thereof | 北京普世安生物科技有限公司 | 2023-04-25 | — | — | CN | claimed |
| WO-2022147039-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES INC. (US) | 2022-07-07 | — | — | WO | claimed |
| US-20220096649-A1 | IMMUNOMODULATING POLYNUCLEOTIDE CONJUGATES AND METHODS OF USE | HORIZON TECHNOLOGY FINANCE CORPORATION | 2022-03-31 | — | — | US | claimed |
| US-11203611-B2 | Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use | TOLLNINE, INC. (US) | 2021-12-21 | — | — | US | claimed |
| WO-2020081744-A1 | IMMUNOMODULATING POLYNUCLEOTIDE CONJUGATES AND METHODS OF USE | TOLLNINE, INC. (US) | 2020-04-23 | — | — | WO | claimed |
| EP-3610022-A1 | IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE | Tollnine, Inc. (US) | 2020-02-19 | — | — | EP | claimed |
| WO-2018189382-A1 | IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE | SOLSTICE BIOLOGICS, LTD. (IE) | 2018-10-18 | — | — | WO | claimed |
| EP-3186387-A1 | METHOD OF DETERMINING THE ACTIVITY OF ENZYMES CONVERTING CYTOSINE DERIVATIVES TO URACIL DERIVATIVES IN CELLS, TISSUES AND ORGANISMS | Univerzita Palackého v Olomouci (CZ) | 2017-07-05 | — | — | EP | claimed |
| WO-2016029889-A1 | METHOD OF DETERMINING THE ACTIVITY OF ENZYMES CONVERTING CYTOSINE DERIVATIVES TO URACIL DERIVATIVES IN CELLS, TISSUES AND ORGANISMS | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2016-03-03 | — | — | WO | claimed |
| US-20130171635-A1 | DUAL OLIGONUCLEOTIDE METHOD OF NUCLEIC ACID DETECTION | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-07-04 | — | — | US | claimed |
| US-20090325897-A1 | DESIGNER THERAPY OF PANCREATIC TUMORS | UNIVERSITY OF MIAMI (US) | 2009-12-31 | — | — | US | claimed |
| WO-2008085611-A2 | DESIGNER THERAPHY OF PANCREATIC TUMORS | UNIVERSITY OF MIAMI (US) | 2008-07-17 | — | — | WO | claimed |
| US-6890736-B1 | Methods for producing proteins in cultured cells | IMMUNEX CORPORATION (US) | 2005-05-10 | — | — | US | claimed |
| US-6107030-A | Determining orientation and direction of DNA sequences | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-08-22 | — | — | US | claimed |
| EP-4746905-A1 | RSV VACCINE | Astrazeneca AB (SE) | 2026-05-27 | — | — | EP | disclosed |
| WO-1985001871-A1 | METHOD AND MATERIALS FOR SENSITIZING NEOPLASTIC TISSUE TO RADIATION | GREER SHELDON B | 1985-05-09 | — | — | WO | disclosed |
| US-4210638-A | 5-TRIFLUOROMETHYL-2'-DEOXYCYCTIDINE AND TETRAHYDROURIDINE OR 2'-DEOXYTETRAHYDROURIDINE | PCR, INC. (US) | 1980-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | RNASE1, POLRMT, TERT | DNMT1 384/4885ADRB1 4067/4885DNMT3B 303/4885 |
| US-11203611-B2 | Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use | TYMP, DUT, PAICS | DNMT1 197/4885ADRB1 4437/4885DNMT3B 512/4885 |
| US-20220096649-A1 | IMMUNOMODULATING POLYNUCLEOTIDE CONJUGATES AND METHODS OF USE | PBK, CD47, NCL | DNMT1 314/4885ADRB1 4293/4885DNMT3B 1100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.